Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $350
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $325 to $350.
June 12, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Tiago Fauth maintains an Overweight rating on United Therapeutics and raises the price target from $325 to $350.
The raised price target and maintained Overweight rating from a reputable analyst at Wells Fargo is likely to positively impact United Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100